Reference Range
LMWH:
Prophylactic Reference Range 0.1-0.3 IU/mL
Therapeutic Range 0.5-1.0 IU/mL
Therapeutic range for mechanical heart valve during pregnancy 1.0-1.4 IU/mL
Rivaroxaban:
Stroke prevention in NVAF 20mg OD 184-343ng/mL[1]
Treatment of PE/DVT 20mg OD 189-419ng/mL[1]
Treatment of PE/DVT 10mg OD 7-273ng/mL[2]
Treatment of ACS 2.5mg OD 13-123ng/mL[2]
Apixaban:
Stroke prevention in NVAF 5mg BD 91-321ng/mL[1]
Stroke prevention in NVAF 2.5mg BD 69-221ng/mL[2]
Treatment of PE/DVT 10mg BD 111-572ng/mL[2]
Treatment of PE/DVT 5mg BD 59-302ng/mL[1]
Treatment of PE/DVT 2.5mg BD 30-153ng/mL[2]
Fondaparinux:
2.5mg OD 0.39-0.50ug/mL[1]
7.5mg OD 1.20-1.26ug/ml[1]
[1] Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: A British Society for Haematology Guideline, Baker et al, Brit J Haematol, 2024
[2] Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulant, Douxfils et al, Thromb Haemost, 2021
Biochemistry
Haematology and Transfusion
Clinical Microbiology (Including Virology)
Cellular Pathology
General Information
Immunology
Molecular Pathology
